Skip to main content
. Author manuscript; available in PMC: 2012 Jun 15.
Published in final edited form as: Diabetes Obes Metab. 2008 Nov;10(0 4):23–31. doi: 10.1111/j.1463-1326.2008.00939.x

Table 2.

Summary of autopsy studies comparing β-cell mass in patients with T2DM vs. BMI-matched controls

References N (M/F) BMI Reported decrease in β-cell mass in T2DM
Rahier et al. 1983 [7] 4/4 lean T2DM ; 3/5 lean ND Unknown No significant difference between T2DM vs. ND
Kloppel et al. 1985 [3] 1/5 obese T2DM; 3/1 obese ND; 7/1 lean T2DM; 4/3 lean ND 29 ± 2 (obese T2DM); 30 ± 1 (obese ND); 21 ± 1 (lean T2DM); 20 ± 2 (lean ND) ~50% decrease in β-cell volume in obese T2DM vs. obese ND~60% decrease in β-cell volume in lean T2DM vs. lean ND
Sakuraba et al. 2002 [21] 10/4 lean T2DM; 10/5 lean ND 21 ± 3 (lean T2DM); 21 ± 3 (lean ND) ~30% decrease in β-cell mass vs. ND controls
Yoon et al. 2003 [5] 15/10 lean T2DM; 10/9 lean ND 22 ± 4 (lean T2DM); 23 ± 3 (lean ND) ~50% decrease in β-cell volume in patients with BMI < 25
Butler et al. 2003 [4] 17/21 obese T2DM; 9/10 obese IFG; 15/16 obese ND; 7/9 lean T2DM; 7/10 lean ND 38 ± 1 (obese T2DM); 37 ± 2 (obese IFG); 36 ± 1 (obese ND); 22 ± 1 (lean T2DM); 23 ± 1 (lean ND) ~50% decrease in β-cell volume in obese IFG vs. obese ND; ~65% decrease in β-cell volume in obese T2DM vs. obese ND; ~40% decrease in β-cell volume in lean T2DM vs. lean ND

Abbreviations: IFG, impaired fasting glucose; T2DM, type 2 diabetes; ND, non-diabetic; BMI, body mass index.